Published: 3 March 2022
Publications
Recent approvals: New active ingredients or new indications
Published 3 March 2022
Prescriber Update 43(1): 9
March 2022
For the period 16 October 2021 to 15 January 2022.
Recent approvals of medicines with new active ingredients
Trade name (active ingredient) | Dose form and strength(s) | Therapeutic area |
---|---|---|
Cuprior (trientine) | Film coated tablet 150 mg |
Wilson's disease patients who are intolerant to D-penicillamine therapy |
Mylotarg (gemtuzumab ozogamicin) | Powder for injection 5 mg |
CD33-positive acute myeloid leukaemia |
Trikafta (elexacaftor/tezacaftor/ivacaftor + ivacaftor) | Film coated tablet 100/50/75 mg + 150 mg 50/25/37.5 mg + 75 mg |
Cystic fibrosis patients with at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene |
Ronapreve (casirivimab/imdevimab) | Solution for injection or infusion, single-use or multiuse
vials 120/120 mg/mL |
COVID-19 |
Approved medicines with new indications
Trade Name (active ingredient) | Dose form and strength(s) | New therapeutic area(s) |
---|---|---|
Rinvoq (upadacitinib) | Modified release tablet 15 mg |
Psoriatic arthritis Ankylosing spondylitis |
See the Medsafe website for: